Cambridge, Massachusetts, United States
I’m the CEO of Portal Instruments, where we are redefining how biologic therapies are delivered. We are building a platform that enables high-volume, high-viscosity biologics to move from IV infusion to subcutaneous injection, unlocking a new generation of at-home therapies. Our system combines reusable hardware with software-controlled delivery to enable therapies that were previously not feasible outside the clinic. We have secured development partnerships with leading biotech companies and are now entering a critical phase: scaling from advanced engineering to clinical-ready, manufacturable systems. I’m currently focused on building the team that will make this transition successful, particularly in industrialization, manufacturing, and program execution. In fact, we are currently hiring a Head of Industrialization / Manufacturing to lead this transition. If you’ve taken complex devices from prototype to scale and are interested in building something from the ground up, I’d welcome a conversation.
• Building a drug delivery platform enabling high-volume, high-viscosity biologics to move from IV infusion to subcutaneous delivery • Secured multiple pharma development partnerships with leading biotech companies • Leading transition from advanced engineering to clinical-ready, manufacturable systems • Building the team and execution engine across engineering, industrialization, and program delivery
Co-founder of SynapDx, a molecular diagnostics company developing a blood-based RNA expression test for early detection of Autism Spectrum Disorder (ASD). Helped build and scale the company from concept through clinical, working at the intersection of genomics, bioinformatics, and clinical diagnostics to enable earlier and more objective detection of ASD.
Business Development Intern, Advanced Surgical Systems • Supported evaluation of new product and market opportunities in advanced surgical systems • Conducted market and competitive analysis to inform strategy and potential partnerships
Founding CEO of Aretais Inc., a medical device startup developing a non-invasive continuous glucose monitoring platform using proprietary quantum spectroscopy technology based on Coherent Anti-Stokes Raman Scattering (CARS).
• Developed and led institutional coverage of the nanotechnology sector at Susquehanna International Group (SIG) • Authored industry research and advised hedge funds and portfolio managers on emerging technology trends and investments • Series 7, 86, 87, and 63 licensed